Case report
/l leukocytes were achieved on day +9 post-transplant. At this time a sevdonor were low (both 1/8). Allogeneic peripheral blood stem cells were harvested by leukapheresis after subcutaneere immune haemolytic syndrome occurred and direct antiglobulin test was positive (IgG and C3d). Elution ous administration of G-CSF (granocyte, kindly provided by Bellon, Neuilly, France) (CD34 + 3.5 × 10 6 /kg; CD3 + showed an anti-A specificity. Evolution was rapidly unfavourable related to multiorgan failure. The patient 410 × 10 6 /kg; CD19 + 79 × 10 6 /kg). The conditioning regimen consisted of cyclophosphamide (60 mg/kg) and TBI; died on day +20 post-transplant. Keywords: ABO incompatibility; allogeneic peripheral prevention of GVHD was provided by cyclosporin A (CsA) and methylprednisolone. No deplasmatisation of the blood stem cell transplantation APBSC was performed since anti-A antibody titre of the donor was low. Rapid engraftment occurred since 500/mm 3 and 5600/mm 3 leukocytes were achieved on day +8 and +9, Allogeneic bone marrow transplantation can be successrespectively. Two transfusions of phenotyped and irradiated fully performed despite ABO incompatibility between the A+ RBC and one irradiated platelet transfusion of group donor and recipient. Major incompatibility may cause a A+ were given to the patient on day +7 when Hb was severe haemolytic transfusion reaction at the time of BMT 7.1 g/dl and platelet counts were 6000/mm 3 . On day +9, a due to interaction of donor type RBC with pre-existing severe immune haemolytic syndrome occurred: acute anehost-derived isohaemagglutins. This complication can be mia, backpain, elevation of bilirubin, LDH and serum prevented easily by removing RBC from the marrow graft.
creatinin. Direct antiglobulin test was positive (IgG and On the other hand minor incompatibility, where donorC3d) ( Figure 1 ). Serum testing showed the presence of antiderived antibodies are directed against ABO antigens of the A alloantibodies. The saline indirect antiglobulin test recipient erythrocytes, may lead to delayed immune haeshowed an anti-A specificity and elution in LISS (low ionic molysis caused by transient antibody production from strength saline) solution revealed strong reactivity anti-A donor immunocompetent lymphocytes. This complication (++++). Group O RBC with original recipient phenotype cannot be predicted before BMT, and although the hae-(D+C+E−c+e+K−) were transfused to keep the patient's molysis is generally moderate, 10-15% of patients develop haemoglobin Ͼ7 g/dl. After the onset of haemolysis, the clinically significant haemolysis. 1 patient's blood group appeared O+ using routine testing We report here an early and severe immune haemolysis ABO. After the patient received O+ RBC, a mixed-field occurring after minor ABO incompatibility in allogeneic pattern appeared indicating persistence of A+ RBC and peripheral blood stem cell (APBSC) transplantation.
presence of O+ RBC of transfused origin. Evolution was rapidly unfavourable since day +9 related to acute renal failure and acute respiratory distress syndrome. Direct antiglobulin test was positive until day +15 post-transplan-blastic leukaemia who recovered from the haemolytic reaction after exchange transfusion of one blood volume. Between March 1991 and December 1995, of over 90 transplants performed in our unit, we have encountered 19 cases of ABO-incompatible allogeneic bone marrow transplantation and seven cases of minor incompatibility (O→A n = 3; O→B n = 4). All patients received methotrexate and CsA as GVHD prophylaxis. Four of these seven patients were found to have a very transient and mild increase in serum levels of bilirubin and LDH between day +9 and day +11 post-transplant, probably related to subclinical haemolysis but without any impairment of reconstitution or clinical course.
Of 33 allogeneic peripheral blood stem cell transplants, this is the first case of severe immune haemolysis. We can speculate that the rapid onset and the intensity of haemolysis could be due to the higher quantity of T and B lymphocytes reinfused with peripheral blood cells compared with bone marrow transplant.
We have described here, in a single patient, a second case of early and severe immune haemolysis in the case of so-called 'minor' ABO-incompatible peripheral blood stem cell allotransplantation leading to the patient's death. However, taking into account the rapidly moving field of allogeneic PBS transplant, this fact should lead clinical investigators to pay special attention in the management of ABO incompatibility. stem cell transplantation. Prophylaxis of GVHD was per-
